START.nano is MIT's hard-tech startup accelerator program. Following are companies invited to participate since 2021. Companies that have graduated from the START.nano program are noted with *
3D Architech
3D Architech is a metal 3D printing technology company developing a gel-to-metal conversion technology.
Active Surfaces
Active Surfaces solves revolutionizes solar power with ultra-light, thin modules.
Advanced Silicon Group*
ASG’s LightSense™ biosensor can simultaneously measure the concentration of many proteins and is fast, simple, inexpensive to use, lowering the barriers for protein sensing. This innovation has numerous potential applications that can help enable broad access to better health care for everyone.
Atantares*
Transform medicine with smart chips. Digital chips provide precise program control and provide high-throughput, long-fragment, low-cost, and high-fidelity DNA sequences for synthesis technology.
Atlantic Quantum
Atlantic Quantum is eliminating the barriers to quantum computing by putting quality first—focusing on excellent engineering, making advances in superconducting qubit technology, and deploying scalable hardware architecture.
Axoft
Axoft is developing brain implants made from soft, flexible materials that reduce injury and could treat disorders such as cerebral palsy.
Finwave (formerly Cambridge Electronics)*
As specialists in connectors and everything related to them, Cambridge Electronic Industries designs and manufactures its own connectors and acts as distributor for the world’s best-known connector manufacturers.
Eva Technology
Eva is developing 100X performance analog AI training solutions to replace energy-hungry graphic processing units (GPUs) and enable sustainable large-scale training model development.
Lydian Labs*
Lydian Labs applies scalable additive manufacturing techniques to build thermally-driven reactor systems that use high-efficiency electric heat as the main source of process energy to accelerate the decarbonization of the chemical industry.
Mesodyne
Mesodyne is building a new kind of power generator—the Light Cell—to enable reliable efficient, silent, and portable power generation anywhere, anytime, and from any fuel for applications ranging from unmanned drones and vehicles to sensors in remote locations, dismounted warfighters, and emergency response.
Micromize*
Micromize, Inc is developing novel miniaturized, environment-friendly, and energy-efficient electronics for mobile & wearable devices.
NeuroBionics
NeuroBionics has developed a new kind of neural interface using microscale, flexible, bioelectronic fibers that seamlessly integrate with the body. Each fiber integrates a range of functions, such as electrical, chemical, and optical capabilities to sense and modulate the biological environment.
NeuroNexus
NeuroNexus is a neurotechnology company that develops and commercializes neural interface technologies, instrumentation systems, and analytics and visualization software for neuroscience and clinical applications.
Rectify Pharmaceuticals*
Rectify is developing small molecule disease-modifying therapeutics for patients with serious ABC transporter mediated diseases.
SiPhox
SiPhox is merging biochemistry and photonic chip technology to enable ubiquitous point-of-need and at-home diagnostics.
SiTration
SiTration is developing ultra-durable filtration membranes that cut energy use in challenging industrial separations by combining the low cost, extreme durability, and filtration performance of various state-of-the-art commercial membrane solutions.
TelAztec
TelAztec was founded on developing application specific microstructure designs and processes and subsequently licensing and transferring the processes to larger manufacturing companies.
Tiba Biotech
Tiba BioTech is advancing the RNA medicine field with an improved approach to nucleic acid delivery.
Transaera
Transaera is developing a new class of affordable, energy-efficient, environmentally friendly cooling systems.
WKD.SMRT
WKD.SMRT was intially focused on developing a more intelligent and user-friendly “smart home.” Conversations with innovators in pharma catalyzed a refocus on harnessing these technologies to evaluate changes in function in real-life, with rich contextual understanding, as the basis for de-risking and accelerating clinical trials.